Atossa Therapeutics CEO to Discuss Clinical Progress and Upcoming Milestones at HCW Conference.
ByAinvest
Thursday, Aug 28, 2025 8:36 am ET1min read
ATOS--
(Z)-endoxifen is designed for breast cancer prevention and treatment and is currently in Phase II development for estrogen receptor-positive (ER+) breast cancer. The drug demonstrates potential across multiple stages of breast cancer management, including reducing breast tissue density to lower cancer risk, inhibiting tumor cell activity prior to surgery, and preventing recurrence or new tumor development following initial treatment.
The fireside chat will cover multiple clinical studies' progress and recent encouraging regulatory feedback that could accelerate the development of (Z)-endoxifen. The presentation will be available via webcast with a 90-day replay period on Atossa's investor website. A preview video message from Dr. Quay is currently available.
Atossa Therapeutics' focus on advancing (Z)-endoxifen for metastatic breast cancer highlights its commitment to addressing unmet medical needs in oncology. The company's recent patent grant for enteric oral formulations of (Z)-endoxifen underscores its innovative approach to breast cancer treatment.
The Selective Estrogen Receptor Modulators (SERMs) market is anticipated to witness significant expansion in the coming years, fueled by the increasing prevalence of cancer, heightened awareness of SERM therapies, and a growing pipeline of candidates in clinical trials and regulatory review [2]. Key players in the SERM market include Atossa Therapeutics, Duchesnay, Pfizer, Eli Lilly, and Sermonix Pharmaceuticals.
References:
[1] https://www.stocktitan.net/news/ATOS/atossa-therapeutics-ceo-to-discuss-clinical-progress-and-upcoming-ns3pl09vj43u.html
[2] https://www.barchart.com/story/news/34378449/serm-market-outlook-2034-clinical-trials-fda-approvals-market-size-therapies-companies-by-delveinsight
Atossa Therapeutics CEO Dr. Steven Quay will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 3:00 p.m. ET. Dr. Quay will discuss Atossa's lead program, Z)-endoxifen, a highly potent Selective Estrogen Receptor Modulator (SERM) with dual mechanisms, and provide an update on the company's clinical progress and upcoming milestones.
Atossa Therapeutics (NASDAQ: ATOS), a clinical-stage biopharmaceutical company focused on breast cancer treatment and prevention, has announced that CEO Dr. Steven Quay will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 3:00 p.m. ET. During the presentation, Dr. Quay will provide an update on the company's lead program, (Z)-endoxifen, a highly potent Selective Estrogen Receptor Modulator (SERM) with dual mechanisms.(Z)-endoxifen is designed for breast cancer prevention and treatment and is currently in Phase II development for estrogen receptor-positive (ER+) breast cancer. The drug demonstrates potential across multiple stages of breast cancer management, including reducing breast tissue density to lower cancer risk, inhibiting tumor cell activity prior to surgery, and preventing recurrence or new tumor development following initial treatment.
The fireside chat will cover multiple clinical studies' progress and recent encouraging regulatory feedback that could accelerate the development of (Z)-endoxifen. The presentation will be available via webcast with a 90-day replay period on Atossa's investor website. A preview video message from Dr. Quay is currently available.
Atossa Therapeutics' focus on advancing (Z)-endoxifen for metastatic breast cancer highlights its commitment to addressing unmet medical needs in oncology. The company's recent patent grant for enteric oral formulations of (Z)-endoxifen underscores its innovative approach to breast cancer treatment.
The Selective Estrogen Receptor Modulators (SERMs) market is anticipated to witness significant expansion in the coming years, fueled by the increasing prevalence of cancer, heightened awareness of SERM therapies, and a growing pipeline of candidates in clinical trials and regulatory review [2]. Key players in the SERM market include Atossa Therapeutics, Duchesnay, Pfizer, Eli Lilly, and Sermonix Pharmaceuticals.
References:
[1] https://www.stocktitan.net/news/ATOS/atossa-therapeutics-ceo-to-discuss-clinical-progress-and-upcoming-ns3pl09vj43u.html
[2] https://www.barchart.com/story/news/34378449/serm-market-outlook-2034-clinical-trials-fda-approvals-market-size-therapies-companies-by-delveinsight
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet